ProMIS Neurosciences, Inc. (PMN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

ProMIS Neurosciences, Inc. (PMN) closed at USD 8.29 on 2026-10-14, a change of -24.6 % over the past year, with a market capitalization of USD 78.02M.

ProMIS Neurosciences, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

ProMIS Neurosciences, Inc. key figures

Previous close

USD 8.29 (2026-10-14)

1-year change

-24.6 %

Market cap

USD 78.02M

Enterprise value

USD 24.56M

P/E ratio (trailing)

-0.75

P/E ratio (forward)

-1.92

EPS (trailing)

-11.65

EPS (forward)

-4.54

PEG ratio

n/a

Price to book

1.58

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.83

Employees

10

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for ProMIS Neurosciences, Inc. and compare it with other stocks.